These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 38194896)
1. Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan. Maeda T; Moriwaki K; Morimoto K; Mo X; Yoshioka T; Goto R; Shimozuma K Value Health Reg Issues; 2024 Mar; 40():118-126. PubMed ID: 38194896 [TBL] [Abstract][Full Text] [Related]
2. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up. Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185 [TBL] [Abstract][Full Text] [Related]
3. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. Motzer RJ; Escudier B; McDermott DF; Arén Frontera O; Melichar B; Powles T; Donskov F; Plimack ER; Barthélémy P; Hammers HJ; George S; Grünwald V; Porta C; Neiman V; Ravaud A; Choueiri TK; Rini BI; Salman P; Kollmannsberger CK; Tykodi SS; Grimm MO; Gurney H; Leibowitz-Amit R; Geertsen PF; Amin A; Tomita Y; McHenry MB; Saggi SS; Tannir NM J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661118 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective. Dhanji N; Decimoni TC; Dyer MTD; May JR; van de Wetering G; Petersohn S; Nickel K; Silva A; Muniz DQB; Casagrande D Oliveira AP J Med Econ; 2023; 26(1):1108-1121. PubMed ID: 37632452 [TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan. Paly VF; Hikichi Y; Baker T; Itakura E; Chandran N; Harrison J J Med Econ; 2020 Dec; 23(12):1542-1552. PubMed ID: 33000994 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States. Polyzoi M; Sandhu H; Maervoet J; Yuan Y; Chaudhary MA; Varol N; Lee A; Dale P; Jones C; Lubinga SJ; Penrod JR J Med Econ; 2022; 25(1):660-668. PubMed ID: 35658806 [TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Rini BI; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; George S; Powles T; Donskov F; Tykodi SS; Pal SK; Gupta S; Lee CW; Jiang R; Tannir NM J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549781 [TBL] [Abstract][Full Text] [Related]
8. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Saggi SS; McHenry MB; Motzer RJ ESMO Open; 2020 Nov; 5(6):e001079. PubMed ID: 33246931 [TBL] [Abstract][Full Text] [Related]
9. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Motzer RJ; McDermott DF; Escudier B; Burotto M; Choueiri TK; Hammers HJ; Barthélémy P; Plimack ER; Porta C; George S; Powles T; Donskov F; Gurney H; Kollmannsberger CK; Grimm MO; Barrios C; Tomita Y; Castellano D; Grünwald V; Rini BI; McHenry MB; Lee CW; McCarthy J; Ejzykowicz F; Tannir NM Cancer; 2022 Jun; 128(11):2085-2097. PubMed ID: 35383908 [TBL] [Abstract][Full Text] [Related]
10. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma. Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States. Berling M; Chaudhary MA; Yuan Y; Varol N; Dale P; Testa E; Klint J; Lee A; Lubinga SJ; Penrod JR J Med Econ; 2022; 25(1):703-711. PubMed ID: 35659172 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan. Morimoto K; Moriwaki K; Shimozuma K; Nakayama T J Gastroenterol; 2023 Dec; 58(12):1188-1197. PubMed ID: 37725256 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer. Yang SC; Ou HT; Su WC; Wang SY Cancer Med; 2023 Apr; 12(7):8838-8850. PubMed ID: 36653947 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US. Watson TR; Gao X; Reynolds KL; Kong CY JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401 [TBL] [Abstract][Full Text] [Related]
15. Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067. Baker T; Johnson H; Kotapati S; Moshyk A; Hamilton M; Kurt M; Paly VF Pharmacoecon Open; 2022 Sep; 6(5):697-710. PubMed ID: 36006606 [TBL] [Abstract][Full Text] [Related]
16. First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis. Wan X; Zhang Y; Tan C; Zeng X; Peng L JAMA Oncol; 2019 Apr; 5(4):491-496. PubMed ID: 30789633 [TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan. Mo X; Moriwaki K; Morimoto K; Shimozuma K Clin Drug Investig; 2022 Jul; 42(7):599-609. PubMed ID: 35675029 [TBL] [Abstract][Full Text] [Related]
18. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Leung D; Saggi SS; Lee CW; McHenry MB; Motzer RJ Eur Urol; 2022 Mar; 81(3):266-271. PubMed ID: 34750035 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Tannir NM; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; Flaifel A; Pignon JC; Ficial M; Frontera OA; George S; Powles T; Donskov F; Harrison MR; Barthélémy P; Tykodi SS; Kocsis J; Ravaud A; Rodriguez-Cid JR; Pal SK; Murad AM; Ishii Y; Saggi SS; McHenry MB; Rini BI Clin Cancer Res; 2021 Jan; 27(1):78-86. PubMed ID: 32873572 [TBL] [Abstract][Full Text] [Related]